EP1305018A1 - Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung - Google Patents

Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung

Info

Publication number
EP1305018A1
EP1305018A1 EP00952402A EP00952402A EP1305018A1 EP 1305018 A1 EP1305018 A1 EP 1305018A1 EP 00952402 A EP00952402 A EP 00952402A EP 00952402 A EP00952402 A EP 00952402A EP 1305018 A1 EP1305018 A1 EP 1305018A1
Authority
EP
European Patent Office
Prior art keywords
cis
trans
composition
chromium
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00952402A
Other languages
English (en)
French (fr)
Other versions
EP1305018A4 (de
Inventor
Michael Menard
Susie Rockway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharmaNutrients Inc
Original Assignee
PharmaNutrients Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharmaNutrients Inc filed Critical PharmaNutrients Inc
Publication of EP1305018A1 publication Critical patent/EP1305018A1/de
Publication of EP1305018A4 publication Critical patent/EP1305018A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention generally relates to the treatment of disease states. More specifically, the present invention relates to the prevention and/or treatment of diabetes and/or the modulation of blood glucose levels.
  • Diabetes mellitus is a syndrome characterized by hyperglycemia resulting from impaired insulin secretion and/or effectiveness.
  • the syndrome is associated with the risk of diabetic ketoacidosis or nonketotic hyperglycemic- hyperosmolar coma as well as a group of late complications including retinopathy, nephropathy, artherosclerotic coronary and peripheral arterial disease, and peripheral and autonomic neuropathies. Diabetes has diverse genetic, environmental and pathogenic origins. See Merck Manual, 16th Ed., pp 1106- 1107.
  • Diabetes is classified based on certain clinical criteria, e.g., the presence or absence of a propensity to diabetic ketoacidosis, as well as on ancillary criteria used to segregate specific pathogenic forms of diabetes. Specifically, diabetics are classified into insulin dependent diabetes (Type I) and non-insulin dependent diabetes (Type 11). Merck Manual, id.
  • diabetes is a chronic disease that has no cure. It affects approximately 16 million people in the United States alone and ranks as the sixth leading cause of death by disease. The estimated 16 million people who have diabetes in the United States includes over 5 million that have not yet been diagnosed with the disease. Not only is diabetes one of the leading causes of death in the United States, it is also a major cause of blindness and kidney disease. The estimated cost of treating diabetes approaches $100 billion dollars.
  • Type II diabetes accounts for approximately 90 to 95% of diabetes. It is characterized by two primary defects: insulin resistance; and/or impaired pancreatic ⁇ -cell function, either delayed or inadequate insulin synthesis or release.
  • Type II diabetes In treating and/or controlling at least Type II diabetes, typically the first avenue chosen is dietary restriction.
  • diet has been found to be rarely effective in gaining complete control of hyperglycemia.
  • Type II diabetics take drugs to control their diabetes.
  • the current drugs on the market are expensive and have undesirable effects.
  • sulphonylurea drugs e.g., glipizide
  • Metformin a class of Biguanide drugs, causes nausea, gastrointestinal discomfort, diarrhea, leaves a metallic taste in the mouth leading to anorexia, and cannot be used by individuals with kidney disease.
  • Another drug, Resulin had been used by 500,000 people, but recently pulled from the market by the F.D.A. because of the liver toxicity and approximately 60 attributable deaths.
  • Thiazolindinediones is another class of anti- diabetic drugs.
  • the present invention relates to methods and/or compositions for controlling blood glucose levels, hyperglycemia, and/or diabetes.
  • the methods and compositions of the present invention can be utilized alone or as a dietary supplement.
  • the present invention provides a method for controlling blood glucose levels, comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid and at least one agent chosen from the group consisting of chromium and ginseng. In an embodiment, approximately 0.1 to about 15 grams per day of conjugated linoleic acid is administered.
  • approximately 0.1 mg to about 1.0 mg per day of chromium is administered. In an embodiment, approximately 1.0 mg to about 9000 mg per day of ginseng is administered.
  • the conjugated linoleic acid is either a pure isomer of octadecadienoic acid, or a mixture of octadecadienoic acid isomers selected from the group consisting of: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans- 10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; metabolites thereof, including but not limited to 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12,
  • the composition includes a flavor.
  • the composition includes an artificial sweetener.
  • the composition is in pill form. In an embodiment, the composition includes both chromium and ginseng.
  • a method of treating diabetes comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid and at least one agent chosen from the group consisting of chromium and ginseng.
  • approximately 0.1 to about 15 grams per day of conjugated linoleic acid is administered.
  • approximately 0.1 mg to about 1.0 mg per day of chromium is administered.
  • approximately 1.0 mg to about 9000 mg per day of ginseng is administered.
  • the composition includes both chromium and ginseng.
  • the present invention also provides a composition comprising conjugated linoleic acid, chromium, and ginseng.
  • a method of treating hyperglycemia comprises the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid and at least one agent chosen from the group consisting of chromium and ginseng.
  • approximately 0.1 to about 15 grams per day of conjugated linoleic acid is administered.
  • approximately 0.1 mg to about 1.0 mg per day of chromium is administered. In an embodiment, approximately 1.0 mg to about 9000 mg per day of ginseng is administered.
  • the composition includes both chromium and ginseng.
  • the present invention provides a method of reducing the risk of diabetes or hyperglycemia in a susceptible patient.
  • the method comprises the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid and at least one agent chosen from the group consisting of chromium and ginseng.
  • a method of reducing the risk of diabetes comprises the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid and at least one agent chosen from the group consisting of chromium and ginseng to a patient at risk of developing diabetes.
  • an advantage of the present invention is to provide an improved method for preventing or treating diabetes.
  • a further advantage of the present invention is to provide a composition for preventing or treating diabetes.
  • an advantage of the present invention is to provide an improved method and composition for maintaining healthy blood sugar levels.
  • Another advantage of the present invention is to provide a product for modulating glucose levels.
  • An additional advantage of the present invention is to provide a dietary supplement for maintaining healthy glucose levels.
  • an advantage of the present invention is to provide a composition and method for normalizing hyperglycemia.
  • Another advantage of the present invention is to provide a dietary supplement for increasing insulin sensitivity.
  • a further of the present invention is to provide a method and composition for lowering hyperinsulinemia. Additional features and advantages of the present invention are described in and will be apparent from the detailed description of the presently preferred embodiments.
  • the present invention provides improved methods and compositions for the treatment of diabetes, hyperglycemia, and the modulation of glucose levels.
  • compositions for modulating blood glucose levels, lowering hyperglycemia, as well as hyperinsulinemia, and preventing or treating diabetes.
  • the compositions of the present invention can be a pharmaceutical product or component thereof, over-the- counter product, and/or dietary supplement, functional or medical food or component thereof.
  • a composition containing mixtures of conjugated linoleic acid, and at least one of chromium and ginseng. It has been found that this combination provides synergistic assistance in reducing or normalizing plasma glucose levels and increasing insulin sensitivity.
  • the product can be provided in a pharmaceutical product e.g., pill or emulsion, dietary supplement, or an over-the-counter product, as well as a functional or medical food, or component thereof.
  • the product is believed to have specific application to hyperglycemic individuals, pre-diabetic and Type II diabetics, reducing the individual's plasma glucose levels and providing a better insulin response.
  • the composition and method can be used to treat diabetes.
  • the composition can control hyperglycemia and increase insulin sensitivity.
  • the composition may also decrease glycosylated hemoglobin. All of these are metabolic factors that eventually lead to blindness, kidney disease, and reduce life expectancy in the diabetic population.
  • compositions of present invention are preferably all naturally occurring substances or derived therefrom; the active ingredients are all naturally occurring substances or derived therefrom.
  • present invention provides a less expensive alternative with no foreseeable side effects.
  • the method and composition comprises administering conjugated linoleic acid, and at least one of ginseng e.g., American Ginseng extract (panax quinquefolium), and chromium.
  • the composition can include non-active ingredients and/or agents such as flavors, artificial sweeteners, excipients, etc. This product is intended to provide a physiologically based means to aid in maintaining normal plasma glucose levels and provide a normal insulin response.
  • Conjugated linoleic acid is believed to be absorbed efficiently into the body in a manner similar to that of other fatty acids, e.g., linoleic acid.
  • the safety of conjugated linoleic acid has been demonstrated in detailed toxicological assessments. It is believed that conjugated linoleic acid is safe for human consumption. The inventors believe that conjugated linoleic acid has favorable effects on glucose homeostasis. Conjugated linoleic acid administration alone is believed to be associated with normalization of glucose metabolism. Further, conjugated linoleic acid is believed to restore insulin sensitivity. It is believed these effects may be related to conjugated linoleic acid's influence on steroid hormone receptors.
  • Conjugated linoleic acid acts similar to a class of antidiabetic drugs, thiazolidinediones, which are potent insulin sensitizers thought to activate peroxisome proliferator-activated receptors.
  • the striking anti-diabetic properties of conjugated linoleic acid appear to be linked to conjugated linoleic acid - activation of PPAR ⁇ .
  • the conjugated linoleic acid of the present invention can comprise a variety of compositions such as those set forth in U.S. Patent No. 5,986,116, the disclosure of which is incorporated herein by reference.
  • the composition of the present invention includes ginseng and chromium.
  • Ginseng has been used as a therapeutic agent for a couple thousand years.
  • Ginseng appears to significantly reduce post-prandial glycemia in diabetic subjects taking ginseng before meals.
  • the mechanism by which ginseng lowers blood glucose is unknown.
  • ginseng may possibly slow digestion and decrease carbohydrate absorption.
  • a second hypothesis is that ginseng increases Glucose Transporter 2 which can increase glucose uptake in cells. This effect may be mediated by nitric oxide. Additionally, ginseng may directly modulate insulin secretion possibly via nitric oxide.
  • Chromium has long been recognized as a necessity for proper human nutrition. The estimated safe and adequate dietary intake of chromium has been estimated at 50-200 ug per day for adults.
  • Chromium regulates carbohydrate and lipid metabolism. Normal dietary intake of chromium in humans is often less than the adequate daily dietary intake. Chromium deficiency may be promoted by increasing its loss through physiological stressors such as physical trauma, acute exercise, lactation, and consuming a diet high in simple sugars. Insufficient chromium intake is associated with signs and symptoms similar to diabetes. It is believed that chromium's mode of action potentiates insulin either by an effect on insulin dependent factors, or by maintaining these functions with less insulin, or a combination of both.
  • compositions comprising conjugated linoleic acid and at least one of chromium and ginseng.
  • the compositions can take a variety of forms, for example, pill, powder or emulsion.
  • composition provides a synergistic effect.
  • a method of providing treatment to diabetics, as well as reducing hyperglycemia, modulating glucose levels, maintaining healthy glucose levels, and increasing susceptibility to insulin is provided.
  • a composition comprising as the active ingredients approximately:
  • ginseng 0 to 33 % by weight ginseng.
  • the form of chromium is chromium chloride.
  • the form of ginseng is American Ginseng.
  • examples of the present invention are as follows: Product Example No. 1 Tablets containing conjugated linoleic acid/American ginseng powder/chromium.
  • each dose of two tablets contain: conjugated linoleic acid powder 500 mg American ginseng (root powder) 700 mg chromium as chromium chloride 0.10 mg
  • the tablets will include the following excipients and flavorings: magnesium stearate, silicone dioxide, croscarmelose sodium, stearic acid, microcrystalline cellulose, calcium phosphate, aqueous base film coat.
  • each dose of two tablets contain: conjugated linoleic acid powder 970 mg American ginseng (25% extract) 28 mg chromium as chromium chloride 0.10 mg
  • the tablets will include the following excipients and flavorings: magnesium stearate, silicone dioxide, croscarmelose sodium, stearic acid, microcrystalline cellulose, calcium phosphate, aqueous base film coat.
  • each dose of two capsules contain: conjugated linoleic acid oil 500 mg American ginseng (25% extract) 28 mg chromium as chromium chloride 0.10 mg
  • contemplative examples of the present invention are as follows:
  • Contemplative Example No. 2 As a dietary supplement to prevent the onset of Type II diabetes, the product of the present invention would be administered daily to provide:
  • Contemplative Example No. 4 In order to maintain healthy plasma glucose levels, the product of the present invention would be administered daily to provide:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP00952402A 2000-08-02 2000-08-02 Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung Withdrawn EP1305018A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/021050 WO2002009693A1 (en) 2000-08-02 2000-08-02 Method and compositions for prevention and/or treatment of diabetes and glucose modulation

Publications (2)

Publication Number Publication Date
EP1305018A1 true EP1305018A1 (de) 2003-05-02
EP1305018A4 EP1305018A4 (de) 2006-08-30

Family

ID=21741654

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00952402A Withdrawn EP1305018A4 (de) 2000-08-02 2000-08-02 Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung

Country Status (4)

Country Link
EP (1) EP1305018A4 (de)
JP (1) JP2004505042A (de)
AU (1) AU2000265109A1 (de)
WO (1) WO2002009693A1 (de)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665566A (zh) 2000-09-21 2005-09-07 营养21公司 用铬络合物、共轭脂肪酸和 /或共轭脂肪醇治疗糖尿病、减少身体脂肪、改善胰岛素敏感性、缓解高血糖症和高胆固醇血症的方法和组合物
EP1302114A3 (de) * 2001-10-16 2004-01-14 Loders Croklaan B.V. Mischungen zur Förderung der Glucoseaufnahme
ATE462723T1 (de) * 2004-03-01 2010-04-15 Pharmafrontier Co Ltd Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
CN101505609B (zh) 2006-08-11 2013-07-17 花王株式会社 油脂组合物
US8809560B2 (en) 2011-05-17 2014-08-19 Board Of Trustees Of The University Of Arkansas Trans-, trans-conjugated linoleic acid compositions and use thereof
ES2395529B1 (es) * 2011-06-08 2014-04-11 Pri, S.A. Combinación sinérgica para el tratamiento de la diabetes mellitus tipo 2.
US9062276B2 (en) 2012-12-03 2015-06-23 Board Of Trustees Of The University Of Arkansas Conjugated linoleic acid rich vegetable oil production from linoleic rich oils by heterogeneous catalysis
CN103190611A (zh) * 2013-03-17 2013-07-10 王伟 一种具有降糖功能的菊花胶囊及其制备方法
CN105658093A (zh) * 2013-08-26 2016-06-08 刘新丰 用于预防和治疗第2型糖尿病的营养品组合
CN107243043A (zh) * 2017-08-17 2017-10-13 刘明州 一种治疗糖尿病和控制其并发症发生的中药

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265772A2 (de) * 1986-10-27 1988-05-04 Abbott Laboratories Flüssige Nährwert-Tabelle für Glukose-Intoleranz
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
WO1998042211A2 (en) * 1997-03-24 1998-10-01 Progressive Research Labs Nutritional supplements for improving glucose metabolism
US5976548A (en) * 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
WO2000012080A1 (en) * 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management
US6063820A (en) * 1997-03-20 2000-05-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Medical food for diabetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037624B1 (de) * 1997-12-12 2005-11-23 Purdue Research Foundation Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265772A2 (de) * 1986-10-27 1988-05-04 Abbott Laboratories Flüssige Nährwert-Tabelle für Glukose-Intoleranz
US5976548A (en) * 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
US6063820A (en) * 1997-03-20 2000-05-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Medical food for diabetics
WO1998042211A2 (en) * 1997-03-24 1998-10-01 Progressive Research Labs Nutritional supplements for improving glucose metabolism
WO2000012080A1 (en) * 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MCCARTY M F ET AL: "Rationales for micronutrient supplementation in diabetes." MEDICAL HYPOTHESES. FEB 1984, vol. 13, no. 2, February 1984 (1984-02), pages 139-151, XP009069813 ISSN: 0306-9877 *
MCCARTY M F: "TOWARD A WHOLLY NUTRITIONAL THERAPY FOR TYPE 2 DIABETES" MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 54, no. 3, March 2000 (2000-03), pages 483-487, XP001105930 ISSN: 0306-9877 *
PELTON R: "SUPPLEMENTS CAN FORESTALL DIABETES COMPLICATIONS WITH 64 MILLION DIABETES-RELATED SCRIPTS DISPENSED EACH YEAR, OPPORTUNITIES FOR NUTRITIONAL COUNSELING ABOUND" AMERICAN DRUGGIST, vol. 216, no. 8, 1999, pages 52-53, XP000908773 ISSN: 0190-5279 *
See also references of WO0209693A1 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US11733196B2 (en) 2012-09-11 2023-08-22 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US11131643B2 (en) 2012-09-11 2021-09-28 Aseko, Inc. Method and system for optimizing insulin dosages for diabetic subjects
US10629294B2 (en) 2012-09-11 2020-04-21 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US10410740B2 (en) 2012-09-11 2019-09-10 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9773096B2 (en) 2012-09-11 2017-09-26 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9811638B2 (en) 2012-09-11 2017-11-07 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US10102922B2 (en) 2012-09-11 2018-10-16 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9965596B2 (en) 2012-09-11 2018-05-08 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9892235B2 (en) 2014-01-31 2018-02-13 Aseko, Inc. Insulin management
US9604002B2 (en) 2014-01-31 2017-03-28 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9965595B2 (en) 2014-01-31 2018-05-08 Aseko, Inc. Insulin management
US11783945B2 (en) 2014-01-31 2023-10-10 Aseko, Inc. Method and system for insulin infusion rate management
US11857314B2 (en) 2014-01-31 2024-01-02 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US10255992B2 (en) 2014-01-31 2019-04-09 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US11621074B2 (en) 2014-01-31 2023-04-04 Aseko, Inc. Insulin management
US9710611B2 (en) 2014-01-31 2017-07-18 Aseko, Inc. Insulin management
US10453568B2 (en) 2014-01-31 2019-10-22 Aseko, Inc. Method for managing administration of insulin
US10535426B2 (en) 2014-01-31 2020-01-14 Aseko, Inc. Insulin management
US11783946B2 (en) 2014-01-31 2023-10-10 Aseko, Inc. Method and system for insulin bolus management
US10811133B2 (en) 2014-01-31 2020-10-20 Aseko, Inc. System for administering insulin boluses to a patient
US11081233B2 (en) 2014-01-31 2021-08-03 Aseko, Inc. Insulin management
US11804300B2 (en) 2014-01-31 2023-10-31 Aseko, Inc. Insulin management
US9504789B2 (en) 2014-01-31 2016-11-29 Aseko, Inc. Insulin management
US11158424B2 (en) 2014-01-31 2021-10-26 Aseko, Inc. Insulin management
US11311213B2 (en) 2014-01-31 2022-04-26 Aseko, Inc. Insulin management
US11468987B2 (en) 2014-01-31 2022-10-11 Aseko, Inc. Insulin management
US11490837B2 (en) 2014-01-31 2022-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US10403397B2 (en) 2014-10-27 2019-09-03 Aseko, Inc. Subcutaneous outpatient management
US11678800B2 (en) 2014-10-27 2023-06-20 Aseko, Inc. Subcutaneous outpatient management
US11694785B2 (en) 2014-10-27 2023-07-04 Aseko, Inc. Method and dosing controller for subcutaneous outpatient management
US10128002B2 (en) 2014-10-27 2018-11-13 Aseko, Inc. Subcutaneous outpatient management
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US10380328B2 (en) 2015-08-20 2019-08-13 Aseko, Inc. Diabetes management therapy advisor
US11574742B2 (en) 2015-08-20 2023-02-07 Aseko, Inc. Diabetes management therapy advisor
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor

Also Published As

Publication number Publication date
EP1305018A4 (de) 2006-08-30
JP2004505042A (ja) 2004-02-19
AU2000265109A1 (en) 2002-02-13
WO2002009693A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2002009693A1 (en) Method and compositions for prevention and/or treatment of diabetes and glucose modulation
US5962030A (en) Dietary supplement and method of treatment for diabetic control
JP4125791B2 (ja) 糖尿病患者用医療栄養物
US7989005B2 (en) Corosolic acid formulation and its application for weight-loss management and blood sugar balance
Jouad et al. Hypoglycaemic effect of Rubus fructicosis L. and Globularia alypum L. in normal and streptozotocin-induced diabetic rats
CN103238897B (zh) 一种适用于糖尿病人的复合植物固体饮料
CN100374155C (zh) 促胰岛素肽和营养物的用途，肠胃外营养组合物和药物
JP3699124B2 (ja) タイプｉｉ糖尿病のピコリン酸クロム高用量治療
US20080102137A1 (en) Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
US4735967A (en) Method for desensitizing the gastrointestinal tract from food allergies
JP3825469B2 (ja) Ｉｉ型糖尿病治療薬剤としてのケトコナゾール、および、その関連物質の使用法
TWI406666B (zh) Niu Zhangzhi for the treatment of diseases
WO1995017889A1 (fr) Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle
KR100479968B1 (ko) 위장 리파아제 억제제의 용도
WO2011163183A2 (en) Methods for delaying progression of diabetes using salacia oblonga extract
WO2002007768A1 (en) Dietary supplement compositions
EP2651251B1 (de) Zusammensetzung zur behandlung von unfruchtbarkeit
Strauss THE THERAPEUTIC USE OF VITAMIN B, IN POLYNEURITIS AND CARDIOVASCULAR CONDITIONS: CLINICAL INDICATIONS
WO2004085462A2 (en) Method and composition for decreasing ghrelin levels
Joffe et al. Gymnema sylvestre lowers HbA1c
US20040097429A1 (en) Method for the reduction of the mammalian appetite
EP0561744A1 (de) Präparate zur Steuerung des Stoffwechsels von Kohlehydraten und Lipiden, die Chrom und Vitamine E und C enthalten
JP2003159028A (ja) 花粉症治療用食品
KR20040010666A (ko) ２ 형 인슐린 내성 당뇨병 환자의 치료를 위한 비오틴과회합된 아세틸 ｌ-카르니틴의 용도
EP1964558A1 (de) Pharmazeutische zusammensetzungen mit darm-lipase-hemmenden substanzen in kombination mit einem chrom dinicotinat o-koordinierten komplex zur behandlung und kontrolle von fettsucht und übergewicht

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030128

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060728

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20060725BHEP

Ipc: A61K 33/24 20060101ALI20060725BHEP

Ipc: A61K 31/201 20060101AFI20060725BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061027